ALK-Abelló (CPSE:ALK B) Launches Neffy In Canada, Is The Valuation Gap Justified?
ALK-Abelló (CPSE:ALK B) shares are in focus after the company reported that neffy, its epinephrine nasal spray for emergency treatment of anaphylaxis, is now available across Canada following Health Canada approval earlier this year.
See our latest analysis for ALK-Abelló.
The neffy launch comes after a strong period for ALK-Abelló, with the stock posting a 1-year total shareholder return of 20.15%, even as the 90-day share price return declined 13.69% and the year-to-date share price return is down 2.65%. This suggests that longer term momentum has so far outweighed recent weakness around the current DKK220.6 level.
If this kind of product news has you rethinking the allergy and immunology space, it can be useful to compare against other healthcare names using a focused screener like 128 healthcare AI stocks
After a strong multi year total return and a recent pullback to around DKK220.6, ALK-Abelló now trades at a sizeable discount to analyst targets and some intrinsic estimates. How far does that gap sit from a reasonable view of fair value?
Most Popular Narrative: 25.8% Undervalued
Based on the most followed narrative, ALK-Abelló's fair value of DKK297.50 sits well above the last close at DKK220.60, which frames the current discount as a valuation gap that hinges on execution in allergy immunotherapy and anaphylaxis.
Recent successful launches and positive momentum for pediatric indications of ACARIZAX and ITULAZAX respiratory tablets are expanding ALK-Abelló's addressable patient pool among children and adolescents, a segment with increasing allergy prevalence globally, supporting sustained top-line revenue growth as these products gain market share.
Want to see what underpins that valuation gap. The narrative leans on steady revenue expansion, firmer margins, and a rich earnings multiple that assumes allergy treatments remain in high demand. Curious how those moving parts fit together into a single fair value number.
Result: Fair Value of DKK297.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, ALK-Abelló still faces real execution risk if neffy uptake is slower than analysts assume, or if higher R&D and capacity spending compresses margins.
Find out about the key risks to this ALK-Abelló narrative.
Another View on ALK-Abelló Using Earnings Multiples
The 25.8% discount to fair value from the narrative model points one way. The current P/E of 38.2x tells a different story. It is well above the European pharmaceuticals average of 21.5x, the peer average of 13.9x, and the fair ratio of 18.8x, which implies higher valuation risk if market expectations ease.
If you put more weight on earnings multiples, it is worth asking whether ALK-Abelló grows into this premium or whether the market eventually leans closer to the fair ratio and industry levels.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed tone so far around ALK-Abelló, it makes sense to move quickly and test the numbers yourself instead of relying on a single view. To see what the market currently likes about the business, review the 4 key rewards
Looking for more investment ideas beyond ALK-Abelló?
If ALK-Abelló has sharpened your interest, use the Simply Wall Street Screener to quickly surface fresh ideas that match your own risk and return preferences.
- Target potential upside with focused opportunities that screen for companies trading below their estimated worth using the 255 high quality undervalued stocks.
- Strengthen your income stream by hunting for companies with higher yields and resilient payouts through the 439 dividend fortresses.
- Prioritise resilience first and search for companies with steadier profiles and lower risk signals using the 302 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com